ConductScience.org, home

Paper22198540

Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.

Perkins JB and 10 others. Biol Blood Marrow Transplant, 2012. Cited by 48 papers, by iCite.

Cite this record

ConductScience Library. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Papers, record 22198540. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22198540

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
PubMed
Journal
Biol Blood Marrow Transplant
PubMed
Year
2012
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
48
iCite
Relative citation ratio, by iCite
1.93
iCite
Revised in PubMed
2016-04-10
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Perkins JBJanelle B
2Kim JJongphil
3Anasetti CClaudio
4Fernandez HFHugo F
5Perez LELia E
6Ayala EErnesto
7Kharfan-Dabaja MAMohamed A
8Tomblyn MRMarcie R
9Sullivan DMDaniel M
10Pidala JAJoseph A
11Field TLTeresa L

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
BusulfanMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Myeloablative AgonistsMajor topic
Transplantation ConditioningMajor topic
VidarabineMajor topic
Adolescent
Adult
Aged
Area Under Curve
Drug Administration Schedule
Drug Dosage Calculations
Female
Hematologic Neoplasms
Humans
Male
Middle Aged
Prospective Studies
Recurrence
Survival Rate
Transplantation, Homologous
Treatment Outcome

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30CA076292NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00361140Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)Results

Source ClinicalTrials.gov

Download CSV of trials

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.

PMIDTitleJournalYearIn PapersSource
41981079Busulfan pharmacokinetics in adults - a real-world evaluation of intra-individual variability and the impact of obesity and deferasirox.Bone Marrow Transplant2026https://conductscience.org/library/papers/41981079PubMed
41557115Association of busulfan area under the curve with the development of neurotoxicity in children and adolescents receiving busulfan-containing conditioning regimens for stem cell transplantation.Int J Hematol2026https://conductscience.org/library/papers/41557115PubMed
39271948A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT).Bone Marrow Transplant2024https://conductscience.org/library/papers/39271948PubMed
38036818Determination of Busulfan and Melphalan in Plasma by Turbulent Flow Chromatography-Tandem Mass Spectrometry.Methods Mol Biol2024https://conductscience.org/library/papers/38036818PubMed
34523110Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.Int J Hematol2021https://conductscience.org/library/papers/34523110PubMed
34453497Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.CPT Pharmacometrics Syst Pharmacol2021https://conductscience.org/library/papers/34453497PubMed
33512420The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury.Blood2021https://conductscience.org/library/papers/33512420PubMed
33231122Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.Leuk Lymphoma2021https://conductscience.org/library/papers/33231122PubMed
33179758
Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology.
Eur J Clin Pharmacol2021https://conductscience.org/library/papers/33179758PubMed
32886279Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.Int J Hematol2021https://conductscience.org/library/papers/32886279PubMed
31834435Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.Cancer Chemother Pharmacol2020https://conductscience.org/library/papers/31834435PubMed
31376591Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci2019https://conductscience.org/library/papers/31376591PubMed
31136799Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/31136799PubMed
30108322Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.Bone Marrow Transplant2019https://conductscience.org/library/papers/30108322PubMed
29469189Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.Br J Clin Pharmacol2018https://conductscience.org/library/papers/29469189PubMed
29250116Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Adv Hematol2017https://conductscience.org/library/papers/29250116PubMed
29238995Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?J Clin Pharmacol2018https://conductscience.org/library/papers/29238995PubMed
28766962Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Expert Opin Drug Metab Toxicol2017https://conductscience.org/library/papers/28766962PubMed
28733264The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.Biol Blood Marrow Transplant2017https://conductscience.org/library/papers/28733264PubMed
28368376Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.Bone Marrow Transplant2017https://conductscience.org/library/papers/28368376PubMed

See all 31 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
HLA-A3105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
HLA-B3106PubTator's text mininghttps://conductscience.org/library/genes/3106NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
FLUDARABINECHEMBL1568Results1https://conductscience.org/library/drugs/CHEMBL1568ChEMBL
BUSULFANCHEMBL820Results1https://conductscience.org/library/drugs/CHEMBL820ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22198540

GET https://conductscience.org/api/papers/v1/22198540/cited_by?page=2